Vanguard Group Inc. acquired a new position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 648,735 shares of the company’s stock, valued at approximately $11,586,000.
Separately, BNP Paribas Financial Markets acquired a new position in shares of ArriVent BioPharma during the first quarter worth $83,000. Institutional investors own 9.48% of the company’s stock.
ArriVent BioPharma Trading Up 3.2 %
AVBP opened at $23.11 on Wednesday. ArriVent BioPharma, Inc. has a one year low of $14.35 and a one year high of $25.95. The business’s 50-day simple moving average is $19.46 and its 200-day simple moving average is $19.13.
Wall Street Analyst Weigh In
Read Our Latest Research Report on AVBP
ArriVent BioPharma Company Profile
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
See Also
- Five stocks we like better than ArriVent BioPharma
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- About the Markup Calculator
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Want to see what other hedge funds are holding AVBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ArriVent BioPharma, Inc. (NASDAQ:AVBP – Free Report).
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.